Amphion Innovations Partner Company Motif Biosciences Closes $1m Financing.NEW YORK New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of -- Amphion Innovations plc, a builder of companies in life sciences and technology, today announces that one of its partner companies, Motif Biosciences, Inc, a population genetics Population genetics The study of both experimental and theoretical consequences of mendelian heredity on the population level, in contradistinction to classical genetics which deals with the offspring of specified parents on the familial level. company in the Arabian Gulf Arabian Gulf: see Persian Gulf. Region, has raised $1 million in a Series C financing. Amphion, which owns 42% of Motif, has invested $400,000 as part of this round. Motif is in the process of raising up to $3 million in capital and anticipates that it will conclude additional financing rounds in the coming months. The continued development of Motif demonstrates Amphion's commitment to building companies that are addressing important needs in the marketplace. Motif is a population genetics company focused on discovering genes causing common diseases by utilising human genetic data from the Persian/Arabian Gulf region, where the populations are far less genetically diverse and thus much easier to analyse an·a·lyse v. Chiefly British Variant of analyze. analyse or US -lyze Verb [-lysing, -lysed] or -lyzing, through applied genomics applied genomics Molecular genetics Molecular medicine The use of genetic information to diagnose, prognosticate and manage disease, based on the techniques of PCR, real time-PCR, DNA sequencing, and gene rearrangement studies for leukemia and lymphoma. . Motif has leveraged its resources to develop a patent-pending methodology for collecting and analysing genetic data. Over the next five years, more than half of the world's top selling drugs will go off patent and as a result, pharmaceutical companies are spending billions of dollars on developing new compounds, many of which never even make it to phase three testing. There is a significant need for drug companies to develop their pipelines more efficiently, and by applying discoveries made possible by the mapping of the human genome The human genome is the genome of Homo sapiens, which is composed of 24 distinct pairs of chromosomes (22 autosomal + X + Y) with a total of approximately 3 billion DNA base pairs containing an estimated 20,000–25,000 genes. researchers can better understand the underlying mechanisms of hard-to-treat diseases such as diabetes, asthma and autism autism (ô`tĭzəm), developmental disability resulting from a neurological disorder that affects the normal functioning of the brain. It is characterized by the abnormal development of communication skills, social skills, and reasoning. . The latest round of financing will support research taking place in the areas of type-2 diabetes and asthma. Amphion's close involvement with Motif also underscores its commitment to establishing itself in the Gulf region, the world's third fastest growing economy. Earlier this year, Amphion announced a Heads of Agreement Heads of Agreement A non-binding document outlining the main issues relevant to a tentative partnership agreement. Notes: It is the draft used by lawyers when drawing up the contract. It serves as a guideline for both parties before any documents are legalized. with two prominent Kuwaiti families to establish a joint venture focused on the support and development of several Gulf-based life sciences and technology companies. Amphion's chief executive officer, Richard C.E. Morgan, said: "Motif represents a great opportunity for Amphion as drug companies are facing an uphill battle Uphill Battle was an metalcore band with elements of grindcore and noisecore. The group was based out of Santa Barbara, California, USA. History Uphill Battle got some recognition releasing their self-titled record on Relapse Records. to quickly develop new and better drugs. Motif has a unique expertise in collecting and analysing genetic data, which allows for drug companies to apply principles of genomics efficiently as they race to develop new drugs that can treat some of the most challenging and chronic disease conditions." Zaki Hosny, chief executive officer of Motif, added: "We are excited that investors see the tremendous value in what we do. We have assembled as·sem·ble v. as·sem·bled, as·sem·bling, as·sem·bles v.tr. 1. To bring or call together into a group or whole: assembled the jury. 2. a world class collection of scientists to undertake the highly complex task of cataloging and analysing large amounts of genetic data that we believe contain answers to some of the most difficult questions in medicine today." As part of Motif's ongoing commitment to its operations in the Gulf, the Company has named Dr. Faisal Al-Refaei to be its Regional Director in the region. Dr. Faisal most recent assignment was as at the Kuwait Ministry of Health. Dr. Faisal received his Masters in Health Care Administration from the University of Swansea and his Medical Degree from Aberdeen University. About Amphion Innovations plc Amphion Innovations plc is listed on the AIM Exchange in London under the symbol AMP. Amphion's business is the formation, financing, management and development of life sciences and technology companies, working in partnership with corporations, governments, universities and entrepreneurs seeking to commercialize their intellectual property. www.amphionplc.com. About Motif Biosciences, Inc. Motif BioSciences, Inc. (http://www.motifbio.com) is a population genetics company focused on discovering genetic causes of major diseases by interpreting the wealth of genomic genomic pertaining to a genome. genomic clone see clone. genomic DNA the DNA sequences making up the genome of an individual. genomic library see gene bank. data from Arabian Gulf Region. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion